文献速递冠心病血脂与心血管预防

急性冠脉综合征后三联与双联降脂治疗的随机对照试验

Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial.
PubMed 文献 · Circulation · 2025-11-07

ES-BempedACS 试验在西班牙 12 家医院纳入 206 例 ACS 患者,随机比较高强度他汀+依折麦布+贝派地酸三联治疗与高强度他汀+依折麦布双联治疗。8 周时 LDL-C <55 mg/dL 的达标率在三联组为 59.4%,双联组为 53.1%(P=0.376),两组不良反应无差异。

要点

  • ACS 后 8 周内双联与三联降脂治疗均可使超过 50% 患者 LDL-C 达标(<55 mg/dL)。
  • 在双联基础上加用贝派地酸未显著提高 8 周 LDL-C 达标率。
  • 三联治疗(含贝派地酸)安全性良好,不良反应与双联治疗无差异。

核心结论

  • ACS 后双联与三联降脂治疗均可使高比例(>50%)患者 8 周时 LDL-C 达标(<55 mg/dL)。
  • 在双联治疗基础上加用贝派地酸安全,但未提高 8 周 LDL-C 达标率。

研究设计与样本

  • 共随机 206 例 ACS 患者(平均年龄 59.5±10.9 岁;女性 21.4%),在 ACS 后 72 小时内随机接受三联降脂治疗或双联降脂治疗。
  • 主要终点为 ACS 后 8 周时 LDL-C <55 mg/dL(<1.4 mmol/L)的患者比例。

主要发现

  • 8 周时 LDL-C <55 mg/dL 的患者比例在三联组为 59.4%,在双联组为 53.1%(P=0.376)。
  • LDL-C 百分比变化在三联组为 57.5±17.8%,在双联组为 56.9±18.5%(P=0.823)。
  • 非高密度脂蛋白胆固醇降低幅度在三联组为 49.0±25.4,在双联组为 49.1±31.2(P=0.970)。
  • 甘油三酯降低幅度在三联组为 14.9±36.9,在双联组为 16.8±36.0(P=0.718)。
  • 两组不良事件无差异。

关键数值与推荐

  • 基线 LDL-C 水平为 133.6±28.8 mg/dL。
  • 主要终点界值为 LDL-C <55 mg/dL(<1.4 mmol/L)。
  • 三联降脂治疗方案为高剂量、高强度他汀+依折麦布+贝派地酸。
  • 标准治疗(双联降脂治疗)为高剂量、高强度他汀+依折麦布。

临床怎么用

  • ACS 后早期启动高强度他汀联合依折麦布的双联降脂治疗可使超过半数患者 8 周内 LDL-C 达标。
  • 在双联治疗基础上加用贝派地酸未显示额外达标获益,但安全性良好。
  • 需更大规模随机研究确认贝派地酸在 ACS 中的角色。

局限性

  • 样本量较小(206 例),可能不足以检测组间差异。
  • 随访时间较短(8 周),未评估长期临床结局。
  • 开放标签设计,尽管终点评估采用盲法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend a stepwise strategy to achieve low-density lipoprotein cholesterol (LDL-C) goals after acute coronary syndrome (ACS). Earlier intensive strategies based on a combination of lipid-lowering therapies (LLTs) could be useful from the onset of ACS. However, the role of bempedoic acid in ACS, particularly when combined with high-intensity statins and ezetimibe, remains uncertain. The aim of ES-BempedACS (Efficacy and Security of Bempedoic Acid in Acute Coronary Syndrome) was to compare the efficacy and safety of triple LLT (high-dose, high-intensity statin+ezetimibe+bempedoic acid) versus standard of care (high-dose, high-intensity statin+ezetimibe) after ACS. METHODS: ES-BempedACS is a multicenter, independent, pragmatic, prospective, randomized, open, blinded end point controlled trial conducted in 12 Spanish hospitals between November 2023 and October 2024. The primary end point was the proportion of patients achieving LDL-C <55 mg/dL (<1.4 mmol/L) at 8 weeks after ACS, comparing triple LLT with standard of care. RESULTS: A total of 206 patients (59.5±10.9 years of age [mean±SD]; 21.4% women) were randomized within the first 72 hours of ACS to triple LLT or standard therapy of high-intensity statin+ezetimibe (ie, dual LLT). The baseline LDL-C level was 133.6±28.8 mg/dL. After 8 weeks, the LDL-C level was reduced to <55 mg/dL in 59.4% of patients in the triple LLT group compared with 53.1% in the control group (dual LLT; P=0.376). The percentage change in LDL-C level was 57.5±17.8% and 56.9±18.5% in the triple and dual LLT groups, respectively (P=0.823). Triple versus dual LLT showed similar results in reduction of non-high-density lipoprotein cholesterol levels (49.0±25.4 in triple LLT versus 49.1±31.2 in dual LLT; P=0.970) and triglyceride levels (14.9±36.9 in triple LLT versus 16.8±36.0 in dual LLT;) P=0.718), without differences in adverse events. CONCLUSIONS: Both dual and triple LLT after ACS allow for high rates (>50%) of adequate LDL-C control (<55 mg/dL) at 8 weeks. Adding bempedoic acid to statin-ezetimibe therapy in the setting of ACS is safe but failed to improve the percentage of patients achieving the LDL-C goal (<55 mg/dL) at 8 weeks. Larger, randomized studies are needed to confirm our findings. REGISTRATION: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2021-006550-31.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Raposeiras-Roubín S, Abu Assi E, Jiménez Méndez C, et al. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial. Circulation. 2025. PMID: 41200807. doi:10.1161/CIRCULATIONAHA.125.075388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。